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Introduction
Chronic airway inflammation is a consistent
finding in patients with cystic fibrosis (CF). Early
bacterial colonization and infection of the
airways with persisting pathogens such as Staphy-
lococcus aureus and Pseudomonas aeruginosa
are generally thought to provoke the activation of
cells of the specific and nonspecific immune
system and the migration of blood neutrophils to
the lung. The consequences of chronic inflamma-
tion are decreasing lung function and premature
death of CF patients. The mechanisms leading to
inflammation in CF patients and the complex cel-
lular interactions in inflammation mediated by a
number of mediators including proteinases, reac-
tive oxygen species and cytokines as well as their
inhibitors are complex. Progress in understand-
ing this important aspect of CF may be acceler-
ated by discussions and collaborations between
researchers with different skills. It is this aim
which led to an international symposium on
inflammation in CF where a number of relevant
topics were discussed and the present know-
ledge summarized by experts in their fields. Such
knowledge will hopefully result in more potent
and selective anti-inflammatory therapeutic strate-
gies, and thus increase life expectancy in CF.
Clinical and pathophysiological aspects of lung
inflammation were discussed in detail. Michel
Aubier, Paris, France focuses on comparti-
mentalized lung inflammation in patients with
pulmonary infections. Then, .udck Cl/ment,
Paris, France reports on recent studies
showing that inflammation in CF may precede
lung infection in contrast to the paradigm that
infection precedes inflammation. If this finding
can be further substantiated, the mechanisms are
to be elucidated and new ap.proaches to monitor
pulmonary inflammation in very young infants
are needed. Interestingly, the expression and/or
regulation of inflammatory mediators from
macrophages and epithelial cells may be different
in normal individuals and CF patients. Melvin
Berger, Cleveland, LISA reports that CF bron-
chial epithelial cells contain much less IL-10 than
those from normal healthy individuals, hypothe-
sizing whether defective CFTR function could
alter epithelial cell cytokine production. Jean-
Michel Dayer, Geneva, Switzerland pre-
sents the complex network of pro-inflammatory
cytokines and their inhibitors stressing on the
concept of a possible dissociation between
immunosuppressive and anti-inflammatory
actions of cytokine inhibitors and its potential
impact on therapeutic strategies. Damage and
remodelling of CF airway epithelium caused by
inflammation may also facilitate adhesion of P.
aeruginosa as described by Sophie Girod de
Bentzmann, Reims, France.
The mechanisms of neutrophil recruitment to
the CF airway lumen, the release of lysosomal
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enzymes and the preventive strategies have been
of major interest in this symposium. Based on
experimental models of lung inflammation,
Peter Ward, Ann Arbor, USA discusses the
mediators for neutrophil recruitment and lung
disease. Jay" Nadel, San Francisco, USA
describes a complex signalling process involving
compounds from bacteria, the airway epithelium
and the neutrophil causing chemotaxis and lyso-
somal enzyme release. Elaine Tuomanen,
New York, USA reports on trials in which anti-
bodies to CD18 or molecules which bind to
receptors of CD18 blocked neutrophil migration.
Robert Stockley, Birmingham, UK sum-
marizes the current knowledge about the genes
of the neutrophil serine proteinases, elastase,
cathepsin G and proteinase-3 and discusses mod-
ulatory processes for elastase expression during
cell differentiation. Gerd D6ring, Tiibingen,
Getanany reports on trials using aerosolized
proteinase inhibitor to suppress neutrophil elas-
tase activity in CF airways.
Oxidative stress, as a consequence of oxidant/
anti-oxidant imbalances, is another important
topic of this symposium. V&ronique Witko-
Sarsat, Paris, France reviews the current
knowledge on the mechanisms of neutrophil for-
mation of reactive oxygen species and long-lived
oxidants and presents recent data demonstrating
that homozygote and heterozygote CF individuals
overexpress neutrophil oxidative activity. Frank
J. Kelly, London, UK demonstrates that bio-
logical markers of oxidative stress and antioxi-
dant scavengers are present in plasma, urine and
sputum of CF patients, suggesting that antioxi-
dant therapy could reduce lung injury in CF. In
contrast, Dieter Worlitzsch, Ttbingen,
Getanany explains the absence of detectable
hydrogen peroxide in the exhaled breath con-
densates of CF patients with the presence of
high sputum concentrations of myeloperoxidase
and catalase.
Based on the clinical experience, conventional
anti-inflammatory drugs, presented by Michael
Konstan, Cleveland, USA may only reduce
the inflammatory manifestations of the airways;
therefore gene therapy is discussed as an alterna-
tive approach to prevent lung inflammation.
Catherine Figarella, Marseille, France
reports on the expression and function of CFTR
in CF and normal airways. Patricia Lemarc-
hand, Paris, France discusses the hurdles of
gene replacement therapy for defective CFTR and
for oxidative stress. In vitro studies by Meksan-
tier Edehnan, Paris, France reveal that cyto-
kines and aspirin may downregulate CFTR gene
expression suggesting that inflammation may
impair gene therapy. Gabriel Bellon, Lyon,
France reports on the results of a CFTR gene
replacement trial in six CF patients and Claire
Danel, Paris, France focuses on the problem
of lung inflammation consecutive to gene trans-
fer.
In conclusion, Inflammation in Cystic Fibrosis
closely reflects the hostile fce of Janus chosen
by the Editor-in-Chief, Ivan Bont, as ’the symbol
par excellenc for Mediators of Inflammation.
We hope that the basic and novel aspects on the
role of inflammation in CF and therapeutic strate-
gies discussed in this symposium will have an
important impact on the management of chronic
inflammatory lung disease in CF patients.
B6atrice Descamps-Latscha, MD, PhD
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Abstracts
Compartmentalized lung inflammation
in response to infection
Michel Aubier
Service de Pneumologie, Unit& INSERM 408, H6pital
Bichat, 46 rue Henri Huchard, 75018 Paris, France
Normally, bacteria are prevented from reaching
the alveoli by several defense mechanisms
located along the normal upper airways. Further-
more, bacteria reaching the alveoli are usually
phagocytized and killed by resident macro-
phages. When normal clearance mechanisms are
overwhelming, a complex response develops. At
a peripheral tissue site, invasion by a bacterial
pathogen produces an inflammatory response
that is accompanied by the activation of local
macrophages by bacterial products such as endo-
toxin and cell-wall components. The early stage
of infection may be characterized by the genera-
tion of multiple signals, including a cascade of
endogenous host mediators triggered by bacterial
products. Among these mediators, cytokines and
particularly tumour necrosis factor-cz (TNF-cz),
interleukin-1]3 (IL-113), interleukin-6 (It-6) and It-
8 are thought to mediatemany host responses to
bacterial infection. These cytokines are involved
in the response to infection, including the activa-
tion of immune cells leading to the production
of specific antibodies. They are also involved in
the recruitment and activation of monocytes and
neutrophils to areas of infection following activa-
tion of endothelial cells.
Although excessive cytokine production during
severe infection has many deleterious effects that
may lead to death,
2 various animal models
support the beneficial role of cytokines in
natural host resistance to local infection. This
suggests that locally produced cytokines ma
contribute to eradicating the invading pathogen.
Indeed, some cytokines appear to have more
local effects within their tissue of origin than sys-
temic effects.4-6
In this regard, several human and animal
studies have demonstrated significant differences
between the inflammatory response in intravascu-
lar models of infection and in localized bacterial
infection such as meningitis.4’5 However, little is
known about the in situ inflammatory response
developing in the human lung during localized
bacterial infection.
In two recent studies,7’8 the in situ inflamma-
tory response developing in the human lung
during a localized bacterial infection was studied
in 15 patients with unilateral community-acquired
pneumonia (CAP). The local response in the
involved lung was compared with that in the con-
trolateral, non-involved lung as well as with the
systemic blood response. Eight healthy volun-
teers served as control subjects. Concentrations
of tumour necrosis factor- (TNF-a), interleukin-
1]3 (IL-113), and interleukin-6 (IL6) and It-8 were
measured by ELISA in bronchoalveolar lavage
(BAL) fluids (n 15), serum (n 15), and
alveolar macrophage and monocyte culture
supernatant (n 8). The concentrations of
TNF-cz, IL-]3, IL6 and IL-8 in BAL fluid were signifi-
cantly higher in the involved lung than in the
paired non-involved lung (p < 0.01) or in healthy
subjects (p < 0.02, p < 0.01, p < 0.001,
p < 0.0001, respectively). Serum IL-6 concentra-
tions were higher in patients than in control sub-
jects, whereas IL- 1 ]3, TNF-cz and IL-8
concentrations did not differ in the two groups.
Alveolar macrophages from the involved lung
spontaneously released higher concentrations of
IL-1]3, IL-6, and TNF-cz (p < 0.05) than did macro-
phages from the non-involved lung, which served
as control. However, macrophages were hypo-
responsive in terms of cytokine production to
further stimulation by lipopolysaccharide (LPS)
in the noninvolved and involved lung compared
with controls, whereas peripheral blood mono-
cytes were not.
These data in humans provide strong evidence
that during unilateral CAP, the inflammatory
response is compartmentalized within the human
lung and is limited to the site of infection.
Mthough TNF-cz and IL-1]3 are believed to have
synergistic .effects that induce lung damage and
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leakage through the capillary wall,9 a beneficial
role has also been ascribed to cytokines in limit-
ing bacterial spread. The localized and com-
partmentalized production of cytokines within
the lung in unilateral pneumonia confirms that
these substances play an important role in the
local lung response to infection. Concomitantly,
the observed hyporeactivity in LPS-induced cyto-
kine synthesis might be the result of a homeo-
static process that would limit the local
inflammatory response and thus protect the lung
from the deleterious effects of excessive cytokine
production, which might otherwise contribute to
tissue damage and particularly of alveolar epithe-
lial cells.
Among the latter, type II alveolar epithelial
cells (ATII cells) have been shown to play an
active role in the regulation of the inflammatory
reaction within alveolar space. Indeed, ATII cells
are ideally located to have a role in modulating
immunologic activity in the alveolar space and
both in vitro and in vivo data suggest that ATII
cells could participate in the intra-alveolar cyto-
kine network by secreting interleukin-8 (IL-8),
11
interferon,
2 monocTte chemoattractant protein-
1, transforming growth factor beta
4 platelet-
derived growth factor5’ and granulocyte mono-
cyte colony-stimulating factorv and more
recently IL-6 under appropriate stimulation.
8
The latter cytokine has been shown to exert
some anti-inflammatory functions. In vitro, at
pathologic concentrations, 11-6 inhibits T cell
responses via the activation of macrophages that
secrete TGF-[3, a cytokine that impairs both T
18 cell and thymocyte proliferative responses.
Moreover, IL-6 downregulates IL-113 and TNFcz
gene expression in human activated monocytes,
9
modulates the synthesis of czl-anti-trypsin in vitro
in human mononuclear phagocytes
2 and
induces a dysfunction of natural killer functions
of lymphocytes.
21 In vivo, in rats, intra-tracheal
IL-6 partially inhibited the neutrophil alveolitis
induced by intra-tracheal tPS.
22
Thus, it appears that cellular communication
between immune and non-immune cells is an
essential process in the initiation maintenance,
and resolution of the intra-alveolar inflammatory
response. A better understanding of the pro-
cesses which regulate the inflammatory processes
within the alveolar space may lead to a more
rational and new therapeutic approach in patients
with infectious or non-infectious alveolitis.
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Inflammatory processes in cystic fibro-
sis
Annick Cldment
Dpartement de Pneumologie Pdiatrique, H6pital
Armand Trousseau, Paris, France
The pulmonary manifestations of cystic fibrosis
(CF) result from chronic bronchopulmonary
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infection leading to respiratory insufficiency by
obstructive lung disease. Colonization of the
lower respiratory tract by bacteria such as Pseu-
domonas aeruginosa has been thought initially
to be a critical event in the initiation and devel-
opment of inflammatory processes. However, it
is likely that the cascade associated with disease
progression involves first pulmonary inflamma-
tion and subsequently infection of the lower
respiratory tract which may therefore result from
the inflammatory insult.
The current view of the pathogenesis of lung
disease in CF with initial inflammation is sup-
ported by recent studies. Controlled analyses of
bronchoalveolar lavage fluid from infants with CF
have documented the presence of increased
inflammatory parameters including neutrophils
counts, activity of free neutrophil elastase and IL-
8 levels. Interestingly, these markers of pulmon-
ary inflammation were found even in the absence
of common bacterial CF-related pathogens, of
respiratory viruses and of fungi.
These recent observations raise two issues.
First, understanding of the mechanisms asso-
ciated with initiation of the inflammatory
response in infants with CF appears to be critical
for the development of new therapeutic strate-
gies. Several hypotheses can be discussed. The
cells most involved in the onset of inflammatory
response are the local macrophages. From recent
studies, it is believed that airway and alveolar
macrophages are an important source of IL-8 in
CF. The reason for an increased expression of
IL-8 by macrophages is still unclear. It may be
induced by external factors such as the abnormal
mucus which accumulates in the lower airways in
CF. It may also reflect an altered function of the
macrophages. Indeed, expression of the cystic
fibrosis transmembrane conductance regulator
gene has been documented in macrophages and
this gene seems to play a role in the control of
several cellular functions including cytokine pro-
duction and secretion. Another element that may
be involved in the amplification of the inflamma-
tory response is the respiratory epithelium. The
cells that compose the epithelium of the airways
and of the alveoli are known to have the ability
of producing a wide range of inflammatory med-
iators. They serve as part of the local immune
system, providing structures and functions crucial
for the maintenance of normal pulmonary func-
tion. It is now well established that alteration of
the pulmonary epithelium plays an important
role in the pathogenesis of many respiratory dis-
eases. In CF, epithelial cells can participate in the
progressive destruction of airways and lung
tissue through interactions with bacteria and
their products, as well as through interactions
with cells present in the airways. These cell-cell
interactions are certainly involved in the up-regu-
lation of inflammatory mediators released by the
respiratory cells. However, the mechanisms
leading to altered expression of the molecules of
the inflammatory response as well as the role of
cystic fibrosis transmembrane conductance regu-
lator gene in this control remain poorly defined.
The second issue relates to the need of early
markers of inflammatory response in infants.
Indeed, if inflammation is an initial event in
disease progression, efforts should be made to
define tools of interest for evaluation of local
inflammation in very young children. In this view,
bronchoalveolar lavage is certainly of great inter-
est; however, its relative invasiveness precludes
its repeated utilization during the follow-up of
the patients. Clearly, new approaches of pulmon-
ary inflammation evaluation in infants are now
required in order to optimize the therapeutic
strategies which could be proposed. These
approaches should include studies of sputum
samples or of aspirates from the upper airways.
Experimental models of lung inflamma-
tion
Peter/t Ward
Department of Pathology, The University of Michigan
Medical School, Ann Arbor, Michigan, USA
Animal models of inflammation have provided
important information regarding mechanisms by
which inflammatory cellular responses occur and
the manner by which tissue injury develops. The
most comprehensive understanding of acute lung
inflammatory injury in rats has come from the
use of the IgG immune complex model in which
alveolar deposition of immune complexes leads
to in situ complement activation. These com-
plexes, together with complement activation pro-
ducts, activate lung macrophages to generate the
early response cytokine, TNF-cz and IL-1. Concur-
rently, these cells generate the C-C chemokine
MIP-lcz, which seems to have autocrine positive
feed-back effects, enhancing macrophage pro-
duction of TNF-cz and IL-1. The primary role of
these two cytokines is to cause upregulation of
lung vascular ICAM-1 and E-selectin. Through a
sequence of adhesion promoting-interactions,
these adhesion molecules facilitate the influx of
neutrophils into the alveolar compartment.
Neutrophil recruitment requires E-selectin,
1CAM-1 and CDlla/CD18 within the vascular
compartment and CDllb/CD18 and ICAM-1
within the airway compartment. The chemotactic
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influx of neutrophils into lung is mediated at can lead to increased amounts of serum pro-
least in part, by a C-X-C chemokine, MIP-2. teases in the extracellular fluid able to induce
Injury to the alveolar and vascular walls occurs epithelial remodelling. It has been clearly shown
via production of nitric oxide (NO) generated by that human leucocyte elastase can induce a wide
inducible NO synthase (iNOS), which has two variety of epithelial remodelling including
sources in lung: alveolar Type II epithelial cells mucous to serous cell conversion,
5 mucous cell
and macrophages. Induction of iNOS appears to hyperplasia and epithelial shedding] In CF,
be regulated by three cytokines: TNF-a IL-1 and chronic airway infection associated with chronic
interferon-gamma. Lung matrix damage occurs airway inflammation represent sources of epithe-
following release from macrophages and neutro- lial injury. Baltimore et al. have described in an
phils of serine proteinases and metalloprotein- extensive histopathologic study, the intense
ases. remodelling of airway epithelium, in CF patients.
These lung inflammatory reactions are self- Lesion of airway epithelium, which represents the
limited, apparently because of concomitant ultimate degree of epithelial damage is followed
appearance of IL-10 which suppresses macro- by repair. The repair process of airway epithe-
phage production of TNF-: and IL-10. Endogen- lium has been described by Zahm et al.9 in an in
ous production of IL-10 has been shown by the vitro model of wound repair of airway epithe-
appearance of mRNA and IL-10 protein in lung lium. Depending on the size of the wound,
following deposition of immune complexes, airway epithelial cells are able to spread, migrate
Blocking of endogenous IL-10 leads to a signifi- and proliferate in order to restore the integrity
cant increase in lung injury. These data demon- of the epithelial barrier. Denuded basement
strate that lung inflammatory reactions are membrane and in particular laminin
2 represent
mediated by a variety of pro-inflammatory cyto- sites of adherence for Pseudomonas aeruginosa,
kines and regulated by at least one anti-inflamma- one of the most important pathogens recovered
tory cytokine (IL-10). in CF. Airway epithelial cells engaged in the
repair process represent also important sites of
adherence for P. aeruginosa. We have recently
described the significantly increased adherence
Process of lesion and repair of airway of P. aeruginosa to airway epithelial cells which
epithelium spread at the edge of the wound from CF and
non-CF origins. Phenotypic alterations of repair-
Sophie Girod de Bentzmann ing airway epithelial cells, spreading at the edge
INSERM U 314, CHR Maison Blanche, Reims, France of the wound, are responsible for the overex-
pression of epithelial receptors for P. aeruginosa
In the normal human respiratory tract, the pseu- adherence. Among epithelial receptors, asialylated
dostratified airway epithelium is protected from membrane glycolipids such as asialo GM1 were
aerocontaminants including viruses, bacteria and recovered at the surface of repairing airway
pollutants, by the combination of a mucus gel epithelial cells acting as receptors for P. aerugi-
layer and of a mucociliary clearance mechanism nosa adherence. Although asialo GM1 represents
by means of the ciliary activity, a site of adherence at the surface of CF repairing
In pathological conditions, such as in cystic airway epithelial cells, we identified asialo GM1 at
fibrosis (CF), the mucociliary clearance is the surface of non-CF repairing airway epithelial
impaired due, in particular, to hypersecretion cells, acting as receptors for P. aeruginosa.
and hyperviscosity of respiratory mucus. The Moreover, the apical asialo GM1 expression on
defective mucociliary clearance in CF, associated repairing airway epithelial cells decreases along
with marked chronic inflammation creates local the repair process. This suggests that the primary
propitious conditions for epithelial injury. Epithe- defect of CFTR in CF cannot represent the
lial injury can vary from epithelial remodelling, unique explanation for P. aeruginosa adherence
including loss of ciliated cells to epithelial shed- to airway epithelial cells. Moreover, airway epithe-
ding with focal basal cells still attached to the lial cells actively synthesize and secrete fibronec-
14 basement membrane, tin during repair which also represents a site of
Various molecules, bacteria or viruses have adherence for P. aeruginosa.
15 We are currently
been extensively described as being able to identifying the FN receptor on repairing airway
induce such epithelial damages. These include epithelial cells. We hypothesize that dramatic
ciliostastic effects, mucous hyperplasia,
2 and phenotypic alterations of airway epithelial cells
epithelial shedding.’4 during lesion and repair widely contribute to
Apart from bacterial or viral products, local chronic airway infection with P. aeruginosa in
immune response to bacterial or viral infections CF. Moreover, the susceptibility of repairing
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airway epithelium to P. aeruginosa adherence
decreases along the repair process in parallel
to asialo GM1 expression, suggesting that imme-
diately after wounding, the onset of repair of the
airway epithelium represents a critical phase
during which it would be useful to protect the
regenerating airway epithelium.
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CFTR expression in the airways: which
cell is the target of the disease?
Catherine Figarella and Marc Merten
Groupe de Recherche sur les Glandes Exocrines,
Facult de Mdecine, 27 Boulevard Jean Moulin,
13385 Marseille, Cedex 5, France
Cystic fibrosis (CF) lung disease is characterized
by inadequate clearance of airway secretion and
increased mucus production causing obstructive
lung disease and chronic bronchial infections
leading to progressive respiratory failure and
death. The running, hypothesis, by which muta-
tions in the cystic fibrosis transmembrane con-
ductance regulator (CFTR) gene lead to a defect
in mucociliary clearance, is one where the
defects in ion transport (decrease of chloride
conductance) found in epithelia of conducting
airways lead to dehydration of mucus, insipissa-
tion of secretions and defective clearance of
inhaled pathogens. This in turn might explain
why CF airways are liable to infection but does
not explain the persistant colonization with
Pseudomonas aeruginosa and the excessive
mucous production. For instance it is known
that patients with ’immotile cilia syndrome’ have
a more profound slowing of airway mucus trans-
port than that seen in CF, but they suffer only
from mild airway infections.
Critical to an understanding of the basic mole-
cular pathology of the CF airway, is a definition
of the normal expression of CFTR in the human
lung. In a pioneer study, Engelhardt et al., using
in situ hybridization and immunochemistry,
found a very low expression of CFTR in superfi-
cial epithelia of the proximal airways but a pre-
dominant site of CFTR expression in
submucosal glands. In these glands, high levels
of CFTR-RNA and protein are found in all cells
of serous tubules of the distal gland, and in 1-
3% of cells in the more proximal collecting
ducts. Using immunogold electron microscopy,
Jacquot et al. demonstrated further that CFTR
protein was more specifically associated with the
secretory granules of glandular serous cells.
2
Later, CFTR was also detected in a subpopula-
tion of epithelial cells at every level of the distal
lung, including proximal, terminal, and respira-
tory bronchioles and the alveoli but with a sub-
stantial variation in the level of CFTR expression
between samples.
The fact that the highest level of CFTR expres-
sion was found in submucosal glands, is not sur-
prising if we consider that the major problem in
CF is an alteration of the rheology of mucus, and
that these glands have long been recognized as
being the main secretory structures in the
mucosa of the bronchotracheal tree. In humans,
the glandular volume is estimated to be about 4
ml, the volume of mucus cells present in the
airways surface epithelium being 1/40 of this
value. The role of submucosal glands in the CF
pulmonary disease does not seem to be in doubt
and the fact that the lungs of knockout mice,
which lack CFTR entirely and normally have ve
few submucosal glands, are minimally affected
supports this hypothesis.
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We recently characterized a primary cell
culture model of human tracheal gland serous
cells (HTGS), which, studied at the third passage,
respond to cholinergic and adrenergic agonists
and synthesize serous secretory markers such as
the secretory leukocyte proteinase inhibitor as
well as high molecular-weight glycoproteins.5’
These cells do express CFTR mRNA and contain
low conductance CFTR-like chloride selective
channels] We could demonstrate that cultured
CF-HTGS cells are subjected to an important
defect in the regulation of the secretory process,
since we observed in these cells a constitutive
hypersecretion of proteins and a hyporesponsive-
ness to the two physiological neurotransmitters:
acetylcholine and norepinephrine.
8 These defects
are specific of CF-HTGS cells and were not
found in cultured HTG cells derived from
patients with other inflammatory diseases like
sarcoidose or chronic obstructive pneumopatho-
logical disease (COPD). This observation indi-
cates that in cystic fibrosis, besides ionic defects,
there is a defect in protein secretion leading us
to suspect a more general defect in the secretory
process. In addition, our preliminary results
show that normal HTGS cells cultured in the pre-
sence of the LPS of P. aeruginosa, behave in the
same way as CF-HTGS cells, strongly suggesting
that CF cells could be constitutively in an inflam-
matory state.
To conclude, many arguments, be they genetic,
molecular or electrophysiologic, are now in
favour of the theory that glandular tracheal cells
are a privileged target of cystic fibrosis. The fact
that their cellular mechanisms are not completely
understood and that these cells are profoundly
lodged in the mucosa will most likely influence
the approaches of somatic gene therapy for the
CF lung.
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Mechanisms of neutrophil recruitment
and activation during lung infection
with Pseudomonas aeruginosa
JayA Nadel
University of California, San Francisco Cardiovascular
Research Institute, San Francisco, CA, USA
The airway submucosal glands and surface goblet
cells normally provide protective mechanisms
against inhaled irritants. In chronic diseases of
the airways, mucus hypersecretion occurs and is
an important cause of airway obstruction in
cystic fibrosis (CF). Large numbers of neutro-
phils and high concentrations of catalytically
active neutrophil proteases exist in CF sputum,
and neutrophil elastase is the most potent secre-
tagogue ever examined. Thus, sputum from
patients with CF is capable of stimulating secre-
tion from gland cells in culture even when the
sputum is diluted 30000-fold! These findings
implicate neutrophil elastase as a potentially
important cause of airway hypersecretion. If neu-
trophil elastase is a cause of the hypersecretion,
how is the elastase released from neutrophils? In
the case of the goblet cells in the lumen, dead
neutrophils are, at least in part, the probable
cause of secretion, because CF sputum contains
high concentrations of active neutrophil elastase.
In the case of gland cells, elastase in the lumen
does not cause secretion and intact neutrophils
do not normally (or easily) release significant
elastase into the medium. I suggest that a
complex signalling process involving the surface
of the secretory cells activates second messen-
gers in the neutrophil, causing exocytosis of elas-
tase-containing granules in close contact with the
secretory cell surface. What is the mechanism of
neutrophil recruitment in CF airways? CF sputum
contains high concentrations of interleukin-8 (IL-
8) and a blocking antibody to IL-8 inhibits sub-
stantially the chemotactic activity of CF sputum,
suggesting that IL-8 plays a significant role in
neutrophil recruitment in CF.
In CF, Pseudomonas aeruginosa (PA) is an
important infecting organism, and the superna-
tant of PA organisms causes time-dependent pro-
duction of IL-8 in airway epithelium. Incubation
of PA supernatant with normal airways obtained
from lung transplant donors resulted in tL-8
expression selectively in the airway epithelium.
To examine whether feedback mechanisms per-
petuate or exaggerate IL-8 expression and neu-
trophil recruitment, we performed animal studies
in vivo. We cloned and expressed IL-8 in dogs
and studied IL-8 expression in a bypassed
segment of trachea. PA supernatant caused early
selective expression of IL-8 in airway epithelium,
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and this was due to a novel, small molecular
weight, water soluble product from PA. Several
hours later, IL-8 was strongly expressed in the
recruited neutrophils, and this was due to PA
lipopolysaccharide (LPS). Thus, neutrophil
recruitment is potentiated. In natural infection,
this would continue until the neutrophils killed
all PA bacteria, and then the mechanism would
be rapidly turned off.
In summary, neutrophil recruitment and
release of products is a complicated process.
Epithelial and neutrophil products form a posi-
tive feed-back system (which is an advantage to
the normal host but apparently disadvantageous
to CF patients). This inflammatory cascade pro-
vides multiple opportunities for potential thera-
peutic intervention.
Prevention of leukocyte diapedesis
bacterial pneumonia
Elaine Tuomanen
Rockefeller University, New York, USA
While it is well accepted that endotoxin is the
major noxious component of gram negative bac-
teria, it is less well appreciated that cell walls are
equally inflammatory in the context of gram posi-
tive disease. The signs and symptoms of pneu-
monia induced by cell walls mimic that of living
bacteria in animal models. Clinical strains and
their isogenic lab derivatives which have defects
in release of cell wall fragments induce an attenu-
ated pattern of disease.
2 These cell wall frag-
ments are potently bioactive with some bein8
specifically toxic to pulmonary epithelial cells,
while others induce the influx of leukocytes or
increased p,ermeability of the pulmonary
4 endothelium. Given that antibiotic therapy
induces a rapid and extremely potent release of
either endotoxin or cell wall fragments, it is
recognized that decreasing injury during infection
necessarily involves an effort to decrease the
inflammation generated by antibiotic therapy
itself. In this context, the ability to modulate leu-
kocyte diapedesis, especially during antibiotic
therapy of pulmonary infection, is currently of
intense interest.
Recently, it has become clear that endotoxin
and cell walls activate inflammatory mediators in
mechanistically different ways.
5 This complicates
the development of strategies aimed at down-
modulating inflammation as a mechanism of
reducing tissue injury. However, a common end-
result of mediator release in both gram positive
and gram negative infection is leukocyte diaped-
esis, a process which in turn is a key contributor
to pulmonary damage. Inhibition of leukocyte
trafficking is therefore not only a rational target
for adiunct therapy to serious pneumonia, it is
also one of the very few targets shared by gram
positive and gram negative,diseases.
Migration of leukocytes from blood into the
alveolar space is a three-step process. The first
step involves margination of the leukocyte by the
interaction of its surface carbohydrates with
selectins on the surfaces of the endothelial cells.
Thus, circulating carbohydrates or selectin analo-
gues, competitively inhibit the ability of leuko-
cytes to find inflamed endothelia. The second
step is the activation of the rolling leukocyte by
chemokines, particularly platelet activating factor
(PAF). PAF plays a major role in pulmonary
inflammation and PAF receptor antagonists are
specifically useful in this context.
4 The third step
is the actual transmigration event from. blood to
alveoles. The key molecules for this event are the
CD18 family of leukocyte integrins. Antibodies to
CD18 block leukocyte accumulation in lung
when given intravenously. Similarly, molecules
that bind receptors for CD18, such as ICAMs on
the endothelium, also block leukocyte move-
ment. However, there is one instance in which
this is not the case. There appears to be a
unique CD18-independent migration that
accounts for 50% of the leukoctyes entering the
lung during pneumococcal pneumonia.4’ Given
the availability of three steps in leukocyte migra-
tion as potential anti-inflammatory targets, there
exists a number of options for leukocyte-directed
anti-inflammatory therapy. This approach is likely
to be fruitful for the development of useful
partner drugs for the amelioration of pulmonary
damage during pneumonia as well as acute sys-
temic states such as ARDS.
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Serineproteinasegenes in leukocytes which the neutrophil elastase gene is not
expressed. Neutrophils from these animals are R A Stockley andK M. McConn
Department of Medicine, Queen Elizabeth Hospital, therefore devoid of this serine proteinase. Infec-
Edgbaston, Birmingham, UK tion studies have shown that the animals have
normal neutrophil recruitment to the lungs but
most imp6ortantly that their survival is much
Leukocytes contain several serine proteinases, enhanced. This suggests that in a heightened
including neutrophil elastase, proteinase 3 inflammatory state associated with infection, too
(Wegeners antigen) and Cathepsin G. These much neutrophil elastase may be detrimental and
three enzymes have been implicated in the would be consistent with our concepts of
pathogenesis of chronic lung disease since both chronic infection in man.7
neutrophil elastase and Cathepsin G have also The human equivalent of the beige mouse is
been shown to cause chronic bronchial disease the Chediak Higashi syndrome. Mature neutro-
and for this reason have been implicated in the phils show abnormal empty granule formation.
pathogenesis of several chronic progressive lung The cells have a chemotactic defect and do not
diseases, contain neutrophil elastase.
At present little is known about these protei- Studies have shown that Cathepsin G is also
nases and their regulation. The genes are distrib- absent in the mature neutrophils and confirma-
uted at different sites. Neutrophil elastase and tion has been obtained recently that proteinase 3
proteinase 3 are found on chromosome 19, is also deficient (unpublished observations in
D13.3 whereas Cathepsin G is found on chro- collaboration with P. Hiemstra, Leiden).
mosome 14 Q 11.2.
2 These genes are expressed However, the studies of bone marrow have
during differentiation of neutrophil in the bone shown that immature neutrophils express both
marrow and currently no evidence exists to indi- the elastase and Cathepsin G gene and that these
cate that they are expressed in the fully differen- enzymes are present prior to full maturation.
8
tiated cell. The best characterized gene, at Since these serine proteinases are coded for on
present, is neutrophil elastase which is expressed different parts of the human genome and since
at the promyelocyte stage during the differentia- at least two of them are expressed in early differ-
tion of the neutrophil and its expression, there- entiation in the bone marrow, it seems likely that
fore, is both tissue specific and time specific the defect in Chediak Higashi syndrome is a
during the differentiation process, common one that is involved in post-translational
The 5’ flanking region of the neutrophil elas- modification of the products. Studies have shown
tase gene contains a CAAT box, TATA box and that all three enzymes are produced as a prepro-
GC rich elements that are consistent with a func- protein. The amino terminal sequence is cleaved
tional promoter. Nucleotide deletion studies have to provide the pro-enzyme and a final dipeptide
suggested that other regulatory sequences are is cleaved at a common site as indicated in the
present within 200 base pairs upstream from the Fig. 1. Recent studies have suggested that the
initiation codon. Han and colleagues recognized defective enzyme may be a cysteine dipeptidase
both positive and negative regulatory sequences but confirmation is awaited.
(-149 to -102 and -196 to -153 respectively) Studies in lung disease have shown that the
whereas Srikanth and Rado
4 identified a further amount of neutrophil elastase in leukocytes from
positive regulatory sequence (-106 to-76). The patients with bronchiectasis is increased com-
sequences are active in promonocytic cells and pared to age matched healthy controls and sub-
not in other cell lines including the hep G2 or jects with emphysema.9 This increase in
HELA cells, indicating that they may be tissue expression of enzyme is not unique since
specific, patients with rheumatoid arthritis and ’diabetes
Studies with promonocytic and promyelocytic have also been shown to have inceased neutro-
cell lines have shown that expression of the elas- phil elastase content of the PMN. The mechan-
tase gene can be decreased by factors that stimu- isms involved in his excess enzyme production
late cell differentiation. In addition the use of
anti-sense oligonucleotide probes, to proteinase
gene transcripts in the HL60 cell line has actually
been shown to induce differentiation towards a
monocyte.
5 The implications of this latter finding
is currently unknown.
The importance of the neutrophil elastase
gene is indicated in several genetic defects. In
animals, the beige mouse is a genetic variant in t. .
Signal Propeptide Mature Enzyme
Sequence
-S-E- I-V-G-G-R-R-A-R-P-H-A- Neutrophil elastase
-G-E- I-I-G-G-R-E-S-R-P-H-S- Cathepsin G I-V-G-G-H-E-A-Q-P-H-S- Proteinase
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are unknown, but may clearly influence the sub-
sequent tissue damage that occurs. The results
would suggest that mechanisms exist for modu-
lating the amount of neutrophil elastase within
the PMN and this presumably occurs during dif-
ferentiation. The reasons for increased neutrophil
elastase content may relate to increased transcrip-
tion, more efficient translation of the messenger
RNA, modifications in intracellular processing
and storage of transport to the cell membrane.
Further studies of these processes may determine
the exact mechanism but also provide potential
therapeutic targets for the modulation of protei-
nase expression.
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Proteinase inhibitor therapy
Gerd D6ring* and Gabriel Bellon**
*Hygiene Institut, Universittt TObingen, Germany and
**H6pital Lyon-Sud, Lyon, France
There is a growing body of evidence that the
consequences of neutrophil activation in the
infected airways of patients with cystic fibrosis
(CF) are at least partly responsible for respira-
tory failure and death in CF. Neutrophils release
lysosomal metalloproteinases and serine protein-
ases upon activation and besides active collagen-
ase and cathepsin G, high levels of elastase have
been detected in bronchial lavage or sputum
samples of CF patients.’2 Apparently, an elas-
tase/anti-elastase imbalance is present in the
inflamed CF airways and high amounts of the
major endogenous elastase inhibitor, czl-protein-
ase inhibitor (czl-PI), are proteolytically cleaved
and inactivated. The other serine proteinase
inhibitors, secretory leukocyte protease inhibitor
(SLPI) and cz2-macroglobulin seem to play a
minor role in protecting the lower respiratory
tract from neutrophil elastase.
Neutrophil elastase plays a major role in the
pathophysiology of chronic inflammation in CF
as well as in other disorders. Besides inactivation
of czl-PI, it cleaves lung elastin and fibronectin,
stimulates airway gland secretion, reduces the
ciliary beat frequency and impairs opsonophago-
cytosis at the levels of immunoglobulins, comple-
ment and the complement receptor CRI on
neutrophils. These events may start very early in
the life of a CF patient, since elevated levels of
elastase have been found in CF patients younger
than 6 months.3’4 In older patients, they may be
present not only in severely diseased patients but
also in CF patients with stable, clinically mild
lung disease.
The proven elastase/anti-elastase imbalance
suggests a strategy of increasing the antiprotei-
nase levels in the lung by supplementation with
suitable inhibitors. A wide variety of inhibitors
has been developed for neutrophil elastase, but
only a few may be applied in humans, czl-PI is
one of them. A trial with aerosolized czl-PI in a
small number of CF patients for several weeks
gave promising results: when 12 patients
received 1.5-3.0 mg/kg every 12 h for 1 week
by aerosol, neutrophil elastase activity was sup-
pressed in the epithelial lining fluid (ELF) and
the anti-neutrophil elastase capacitiy was
restored when ELF 0d-PI reached 8 l.tM/1.
Furthermore, killing of Pseudomonas aeruginosa
in vitro was enhanced. However, in another
ongoing trial in Lyon, in which the same
dose of czl-PI was aerosolized twice daily for 3
days, similar results have not been obtained.
When neutrophil elastase activity was assessed
one day before and 8 days after aerosolization
in bronchoalveolar lavage and daily in sputum
samples no significant reduction of enzyme
activity was reached. Positive results were
obtained in a multicenter study of aerosolized
czl-PI which completed 22 CF patients and
where 100 mg, 200 mg or 350 mg were given
every 12 h for 4 weeks. In all patients except
one, elastase activity decreased and/or the capa-
city to inhibit added exogenous elastase
increased in ELF. However, sputum elastase
activities did not correlate well with ELF activ-
ities. It was concluded that biochemically effec-
tive levels of czl-PI (prolastin) can be safely
delivered but further studies are needed for a
better evaluation of the application of 0d-PI in
CF.
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Oxidative metabolism in polymorpho-
nuclear neutrophils
vdronique Witko-Sarsat and Bdatrice Descamps-
Latscha
INSERM U25, H6pital Necker, 161 rue de Svres
75015, Paris, France
In order to achieve its principal function which is
the host defence against pathogens, neutrophil
can use two different microbicidal systems.
The non-oxygen dependent pathway consists
of proteinases and antibiotic proteins stored in
azurophil granules. Neutrophil elastase, which is
a serine proteinase released upon neutrophil acti-
vation, has led to extensive studies in the context
of cystic fibrosis (CF). The high levels of neutro-
phil elastase in CF airways has evidenced the
importance of neutrophil-derived mediators in
the inflammatory process in CF.
The second microbicidal system is the oxygen-
dependent pathway leading to oxidant genera-
2 tion. Unlike proteinases, no extensive studies on
the oxidant-generating systems have been carried
out in CF. However, a growing body of evidence
has shown an imbalance between oxidants and
antioxidants in CF, thus pointing out an oxidative
stress.
Oxidative metabolism activation, known as the
respiratory burst, first involves NADPH oxidase.
Activation requires cellular components from
both the cytosol and the cell membrane. This
enzymatic complex is an electron transport chain
driven by an NADPH oxidase. The membrane
proteins are composed of a cytochrome b558
which consists of a highly glycosylated large 91
kD subunit (gp91phox, glycoprotein 91 kD pha-
gocyte oxidase) and which contains binding sites
for NADPH and FAD and a small 22 kD protein
subunit (p22 phox). The cytoplasmic subunits
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FIG. 1. Reactions leading to oxidant generation following neu-
trophil activation.
are p47phox (which binds to gp91phox after
phosphorylation by protein kinase C), p67phox
and a GTP-binding protein, Racl or Rac2, which
hydrolyzes GTP in GDP and is involved in the
dissociation of the active complex. After assem-
bly, the NADPH complex is functional, resulting
in the univalent reduction of molecular oxygen
to superoxide anion. This superoxide is con-
verted to hydrogen peroxide (H202) sponta-
neously or by the means of superoxide
dismutase. In the presence of iron salts, super-
oxide anion and hydrogen peroxide may interact
further to produce hydroxyl radicals (OH.) (see
Fig. 1).
Myeloperoxidase is the second important
enzyme in the oxidative metabolism of neutro-
phils. Myeloperoxidase is stored in azurophil
granules and represents 5% of the neutrophil dry
weight. In the presence of H202 and chlorine, it
catalyses the formation of hypochlorous acid
(HOC1).
4 The formation of singlet oxygen, a
potent microbicidal agent, has also been
described.5 HOCl can react with endogenous
amines (R-NH2) to generate chloramines (RNH-
Cl).
6 Taurine, a beta-amino acid considered as a
HOC1 scavenger and very abundant in neutro-
phils is the most common substrate used to
form chloramines. The oxidants such as superox-
ide anion, H202 and even HOC1 are very reactive
and labile species whereas chloramines are
stable enough to accumulate in the extracellular
milieu; they have thus been called ’long-living
oxidants’. The presence of long-living oxidants
have been recently reported in sputum from CF
patients.
7
It becomes evident from several studies that
superoxide anion or H202 may not be the micro-
bicidal species and it is usually admitted thatAbstracts
HOCl, terhaps via the formation of singlet
oxygen,
5 can be the most toxic substance.
8
The exploration of neutrophil oxidative meta-
bolism in CF has led to divergent results,
because of the wide heterogeneity in the clinical
state of the CF patients and because of the dif-
ference in the methodology.
It seems that defects in intracellular transduc-
tion found in CF epithelial cells were not present
at the level of the neutrophil. In fact, increase in
cellular cyclic AMP triggered by several pharma-
cological agents (adrenaline, theophyllin and for-
skolin) had the same inhibitory effect on
neutrophil cellular functions such as superoxide
anion production, degranulation, membrane
depolarization in CF subject as in controls.9 It
has been shown that the luminol enhanced che-
miluminescence which measured the intracellular
MPO-dependent oxidant formation of neutro-
phils stimulated by opsonized zymosan had the
same intensity in CF patients and in controls.
However, the kinetics of the reaction were differ-
ent: the time to reach the maximum was
decreased in CF. Moreover, this parameter
appears to be correlated with the clinical state of
the patients. These authors thus concluded that
neutrophils from CF patients were ’primed’.
Other studies on monocytes and neutrophils
have shown an increase of luminol enhanced
chemioluminescence following stimulation by f-
MLP, PMA and A23187.11
Investigations on neutrophil oxidative metabo-
lism are hampered by the fact that it is difficult
to differentiate between a possible activation
state due to recurrent infections of CF patients
and a possible ’constitutive’ defect which could
be specific of CF. Investigation of neutrophils
from CF heterozygote subjects, who are obligate
carriers of the CFTR mutation and clinically
asymptomatic, could provide a mean to discrimi-
nate between the two possibilities. It has been
reported that monocytes from CF homozygotes
and heterozygotes showed increased adherence
on glass.
12 In .a recent study carried out in our
laboratory, we have shown a disturbance in
MPO-dependent oxidant generation in neutro-
phils from CF homozygotes and heterozygotes as
compared to controls. The mechanism underly-
ing this hyperactivity seems to involve the
sodium/proton exchange system as pharmacolo-
gical blockers of this exchange system such as
amiloride or EIPA or a sodium-deprived buffer
corrected this hyperactivity (Witko-Sarsat et al.,
submitted for publication).
In conclusion, the neutrophil plays a pivotal
role in CF inflammation and remains the more
potent in cellular oxidant-generating systems. It
thus seems of special relevance to explore their
mechanisms of formation, to study the conse-
quence of their massive release as well as the
clinical consequences.
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The role of oxidative stress in cystic
fibrosis
Frank J. Kelly
Cardiovascular Research, The Rayne Institute,
St Thomas’ Hospital, London, UK
Although the genetic defect responsible for cystic
fibrosis (CF) is well characterized, the events
leading to the gradual destruction of lung tissue
and the consequent decrease in lung function
remain unclear. In an attempt to improve this
situation our Group has over recent years,
addressed the specific role of oxidative stress
and antioxidant defences in the pathogenesis of
CF1-5. Two overriding features have characterized
the findings from this series of studies. First,
gross deficiencies of fat-soluble antioxidants such
as cz-tocopherol (vitamin E) have not been
found. This presumably reflects the good clinical
and nutritional management now provided in CF
clinics.
Second and more disturbing, despite relatively
normal antioxidant concentrations, many CF
patients exhibit evidence of oxidative stress.
Blood plasma obtained from CF patients has a
decreased oxygen radical trapping capacity of
plasma in CF patients, indicating an increased
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susceptibility to oxidative damage compared to
control subjects. Confirming this finding, we
have demonstrated the presence of oxidized
lipids (hydroperoxides) and proteins (carbonyls)
in the plasma of CF patients, implying free
radical-mediated tissue damage.
2 In addition, we
have shown that the DNA oxidation product, 8-
hydroxydeoxyguanosine is present in the urine
of CF patients. As already mentioned the inter-
esting, and yet disturbing aspect of all these find-
ings is that oxidative stress was detected in CF
children whose circulating antioxidant defences
(vitamin E, ascorbic acid, uric acid and total
plasma sulphydryls) were within the normal age-
related range. These findings, therefore, not only
provide confirmation that increased radical pro-
duction is a component of CF aetiology, but that
normal concentrations of circulating antioxidants
are not sufficient in many CF patients to offset
the consequences of their increased oxidative
burden.
Oxidative stress and the decline in lungfunction
in CF
Establishing the presence of markers of oxidative
injury in fluids such as plasma and urine has pro-
vided a biochemical basis for free radical damage
in CF, but determining the clinical relevance of
these findings is clearly more important. In this
respect we recently found that the age-related
decrease in lung function in CF children is asso-
ciated with lower plasma cz-tocopherol, ascorbic
acid and sulphydryl concentrations. Moreover,
the age-related reduction in pulmonary function
correlated with elevated plasma malondialdehyde
in CF children.4 In addition, patients with severe
lung dysfunction (FEV1 < 50% predicted) had
higher plasma concentrations of lipid hydroper-
oxides than those with mild to moderate lung
dysfunction (FEV1 > 50% predicted). We believe
that these findings warrant a closer examination
of the association between lung function and
oxidative stress in CF. To this end, studies are
required which focus directly on the lung.
Antioxidant defences and markers of oxidative
stress in sputum
Sputum arises in the lung and as such may
provide a more suitable medium than plasma to
examine for markers of oxidative stress and anti-
oxidants. In a pilot study, conducted in 11 CF
patients we have demonstrated that it is possible,
with minor modifications to existing methods, to
measure cz-tocopherol, uric acid, ascorbic acid
and total sulphydryls in sputum. Indeed, the con-
centrations and composition of these antioxi-
dants indicate that sputum is a reasonable
surrogate for the lining fluids of the upper
respiratory tract. Despite this wide array of extra-
cellular antioxidants, evidence was obtained for
both protein and lipid oxidation in sputum from
CF patients. We have not yet had the opportunity
to determine whether the markers of oxidative
stress in sputum correlate with those present in
plasma of the same patients. Neither have we
addressed the association between antioxidant
defences, markers of oxidative stress in sputum
and lung function in CF patients.
Antioxidant therapyfor CF
Two findings have led us to believe that antioxi-
dant supplementation, to above control levels,
may prove to be a useful therapeutic benefit in
CF. First, markers of oxidative stress, which am
not present in control age-matched children, are
present in many CF patients, whose circulating
antioxidant defences fall within the normal age-
matched range. Second, CF patients with the
highest plasma antioxidant concentrations
exhibit the best pulmonary function. We
hypothesize that CF patients endure cyclic
periods of oxidative stress associated with
chronic respiratory infection and that when this
oxidative stress exceeds the patients pulmonary
antioxidant defences oxidative-lung injury
ensues.5 This injury, in combination with that
arising from the protease/antiprotease imbalance,
contributes to the pulmonary pathology seen in
CF patients and in time results in compromised
lung function. Combating this oxidative stress
with additional antioxidant therapy may help to
reduce lung injury, and hence decrease the rate
of loss of lung function.
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Dieter Worlitzsch, Gunda Herberth and Gerd Doring
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In cystic fibrosis (CF), the most common autoso-
mal recessive disorder of whim populations,
abnormal exocrine gland secretions lead to
chronic endobronchial infections with opportu-
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nistic bacterial pathogens such as Pseudomonas
aeruginosa. As a consequence, large numbers of
neutrophils are recruited to the infected airways
where cell activation and lysosomal enzyme
release occur. Neutrophils respond to stimula-
tion with a burst of oxygen consumption and
the production of reactive oxygen species such
as superoxide anion, hydrogen peroxide, hydro-
xyl radical and possibly singlet oxygen. As with
lysosomal proteinases, these species are not only
released into the phagolysosome but also outside
of the phagocyte where they may be toxic to the
host.
It is not yet certain whether toxic oxygen
metabolites produced by stimulated PMN also
contribute to lung injury in CF, as has been sug-
gested in other airway diseases.
2 However, indir-
ect evidence may support this hypothesis; high
sputum concentrations of extracellular myeloper-
oxidase (MPO), a PMN-derived enzyme which
transforms hydrogen peroxide (H202) into
highly reactive oxygen metabolites, have been
detected in CF patients,-
and lung function has
been inversely correlated with MPO levels.4- In
addition, deficiency of the antioxidant glu-
tathione and increased lipid peroxidation
8 have
been reported to occur in CF patients. The pre-
sence of endogenous scavengers such as uper-
oxide dismutase (SOD) which dismutates
superoxide anion to hydrogen peroxide, or cata-
lase which changes hydrogen peroxide to water
and oxygen, has not been investigated .in CF
sputum or bronchoalveolar lavage samples until
now. The human catalase gene in airway epithe-
lial cells is a ’house keeping gene’ which cannot
be augmented by hyperoxia.
9
Nevertheless, the amount of tissue damage and
degree of protein inactivation by oxidative attack
in CF and other disorders has not been clearly
defined. Of considerable interest is whether al-
proteinase inhibitor (al-PI) undergoes oxidative
inactivation. A number of studies have shown
that Met5, an important residue of the serine
proteinase binding site, is particularly susceptible
to oxidative attack, the result being a substantial
reduction in the ability of the inhibitor to bind
neutrophil elastase.
1
Provided that further proof of the hypothe-
sized oxidant/antioxidant imbalance in CF can
be obtained, which possibilities do we have to
protect the lung epithelium and biological impor-
tant proteins, fatty acids, carbohydrate moieties
and DNA from oxygen radical-induced damage?
Several strategies have been developed including
the application of rhSOD
11 or selenium,
12 aero-
solization of N-acetylcysteine as a precursor of
13 glutathione and the augmentation of the antiox-
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Pro-inflammatory cytokines and their
inhibitors
Jean-Michel Dayer
Division of Immunology and Allergy, University
Hospital, 1211 Geneva 14, Switzerland
Simultaneously to the inflammatory process
mediated by pro-inflammatory substances (cyto-
kines such as 11-1 and TNFcz), the organism
resorts to natural mechanisms which limit the
extension of the inflammation. Among them are:
(1) specific cytokine antagonists at the receptor
level (IL-1 Ra); (2) cytokines whose biological
inhibitory functions oppose pro-inflammatory
cytokines such as IL-1 and TNFcz (e.g. IL-4, 11-13,
11-10, TGFJ3); (3) inhibitors acting as binding pro-
teins to the ligand (e.g. soluble receptors of cyto-
kines) or plasma proteins acting as carriers; (4)
natural enzyme inhibitors converting inactive pro-
cytokines into active ones; (5) enzymes cleaving
cytokine membranous receptors; (6) decrease of
cytokine receptor expression; (7) enzymes
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degrading proinflammatory cytokines; (8) natural
autoantibodies to cytokines.
Inhibition can also be contrived by interfering
at the following levels: (1) the stimulus inducing
the production of proinflammatory molecules
(e.g. anti-CD14) in relation to LPS stimulation;
anti-CD11 and anti-CD69 in relation to cell-cell
interaction resulting in the production of IL-1,
TNFcz, PGE2 and metalloprotease; (2) the trans-
duction, transcription and translational processes;
(3) the maturation and secretion of cytokines; (4)
the functional structure of cytokines (muteins).
Factors to be considered when examining the
concept of cytokine/cytokine inhibitors are: (1)
the chronology of appearance of the molecules;
(2) their relative levels are more important than
absolute levels; (3) the potentially beneficial
effect, for a short period, of a proinflammatory
molecule in host defense; (4) the complexity of
some cytokine systems such as the IL-1 system
which prossesses at least two types of natural
antagonists (II-lRa, II-ISR) leading to the paradox
of enhanced pro-inflammatory activity; (5) the
formation of unstable cytokine/cytokine inhibitor
complexes.
Therefore, the concept of cytokine inhibitors
may not be considered an ’on/off’ but a ’buffer’
system. Another important aspect of the potential
impact of cytokine inhibitors is the dissociation
between their immunosuppressive and anti-
inflammatory action. TNF-R: Fc fusion protein,
for instance, is hundred times more potent, in
inhibiting metalloproteases and PGE2 production
by fibroblasts than in inhibiting T cell prolifera-
tion and cytokine production on T cells. It is
therefore important in devising therapeutical
approaches in the future to pinpoint inhibitors
of cytokines that are relevant primarily in
immune-inflammatory or destructive events.
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Cytokines in cystic fibrosis lung disease
Melvin Berger, Tracy Bonfield, James Panuska and
Michael Konstan
Departments of Pediatrics and Medicine, Case
Western Reserve University School of Medicine,
Cleveland, Ohio 44106, USA
Several characteristics of CF, including the exces-
sive influx of neutrophils into the lungs, cachexia
and hyperglobulinaemia, suggest the involvement
of pro-inflammatory cytokines such as interleukin
(IL)-I, tumour necrosis factor (TNF<z), IL-8 and
IL-6. Because local synthesis and actions of cyto-
kines are often more important than systemic
concentrations and/or effects, we have focused
on measuring cytokine concentrations and deter-
mining their sites of production within the lung
itself, using bronchoalveolar lavage (BAL) and
airway brushing specimens. Concentrations of
the pro-inflammatory cytokines IL-1, IL-6 and
TNF-cz are all dramatically elevated in BAL fluids
from CF patients as compared to healthy con-
trois. While no IL-8 is found in the BAL fluid of
healthy controls, CF patients’ fluids contained
greater than 30 ng/ml of this potent neutrophil
attractant, even when they were stable and
remote from exacerbation. CF patients’ BAL
fluids contained modest elevations of the regula-
tory factors IL-1 receptor antagonist and TNF-cz
soluble receptor fragments but the ratios of
antagonist to cytokine were greatly reduced in
the CF patients. IL-10, a regulatory cytokine,
which suppresses production of the pro-inflam-
matory cytokines, was absent or markedly
reduced in the CF specimens but present at 3.5
ng/ml in specimens from healthy controlsl All of
these differences were more pronounced in CF
patients infected with Pseudomonas as compared
with patients infected with Haemophilus influen-
zae and/or Staphyloccocus aureus, but similar
changes were present in the latter patients as
well. In one case of an infant in which intensive
antibiotic treatment was able to eradicate detect-
able infection, the concentrations of IL-6 and IL-8
fell after treatment but were still markedly ele-
vated as compared with controls. No IL-10 was
detectable before or after antibiotic treatment.
To understand this imbalance towards pro-
inflammatory cytokines, we evaluated the poss-
ible cellular sources of these cytokines in the CF
lung. Fresh macrophages in CF BAL specimens,
fixed and stained immediately after they were
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obtained from the lung, showed positive immu-
nofluorescenc for IL-1, IL-6, IL-8 and TNF-0t and
resembled healthy controls’ macrophages which
had been incubated with lipopolysaccharide in
vitro before staining. In contrast, fresh macro-
phages from the controls which were not incu-
bated in vitro were predominately negative.
Interestingly, fresh macrophages from the CF
patients stained positively for IL-10. This was also
observed in LPS-treated macrophages from
healthy controls but not in untreated controls’
cells. Further studies, aimed at determining the
source of IL-10 in the healthy controls’ lavage
fluid, showed that fresh bronchial epithelial cells
obtained by brushing had positive immunofluor-
escence for IL-10, contained IL-10 mRNA, and
secreted functionally active IL-10 when placed in
primary culture in vitro. CF patients’ bronchial
epithelial cells contained much less IL-10 by
immunofluorescence. These findings suggest that
in the normal lung, the bronchial epithelial cells
produce the anti-inflammatory cytokine IL-10 to
down-regulate local inflammatory responses and
prevent epithelial damage, whereas this suppres-
sive mechanism is lost in the infected lung in CF.
In contrast, in CF the bronchial epithelial cells
are actively producing IL-6 and IL-8, which
further exacerbate the inflammatory process.
Taken together, these observations suggest
that the bronchial epithelial cells may play a
major role in regulating local immunologic and
inflammatory processes in the lung. This hypoth-
esis, in turn, raises the questions of whether
defective CFTR function could alter epithelial cell
cytokine production, even in the absence of
infection; and/or whether the responses of CF
epithelial cells to stimuli that could upregulate IL-
8 production and/or downregulate IL-10 produc-
tion differ from the responses of normal cells.
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CFTR gene regulation by cytokines and
anti-inflammatory drugs
Aleksander Edelman, Franfoise Besanfon* and
Marie-Yvonne Baudouin-Legros
INSERM U323, CHU Necker and *INSERM U417, CHU
St Antoine, Paris, France
Cystic fibrosis results from mutations in a 250 kb
gene encoding the CFTR protein, a cyclic AMP-
regulated Cl- channel. CFTR protein is located in
the apical membranes of secretory epithelial
cells.1’2 Mutations in the gene result in the
altered synthesis, processing or function of the
protein. The dysfunction of this channel is, at
least partly, responsible for defective fluid secre-
tion in CF patients. The disease has pleiotropic
manifestations dominated by abnormalities of the
airway epithelium surface which hypersecretes a
thick mucus favouring inflammation and chronic
infections.
Inflammation triggers the formation of a large
number of both intracellular and tissular media-
tors able to affect the cell functions. For
example, interferons (IFN), a family of multifunc-
tional proteins produced in response to viral and
bacterial infections, are major mediators of the
host defence against the infectious agents.
4 IFN0t
and IFN[3 are mainly synthesized by lymphocytes
and fibroblasts, respectively. IFN,, a key cytokine
of the immune network, is synthesized by T lym-
phocytes and natural killer cells after antigen sti-
mulation, and its crucial role in the defence
against parasitic and viral infections was recently
highlighted.
5 Another mediator of inflammation,
the tumour necrosis factor 0t, TNFcz, is synthe-
sized and released by macrophages/monocytes
as well as by B and T cells, Kupffer cells, glial
cells and adipocytes,
6 and provokes pleitropic
intracellular effects. IFNT and TNF0t also alter
transepithelial ion transport but the mechanisms
responsible for this action are not well defined.
Both the bacterial colonization and the tissular
mediators of inflammation may affect the cell
functions. However, whether they influence
directly or indirectly CFTR function was not
clearly established. This prompted the investiga-
tion of the effects of IFNs and of TNFcz on CFTR
gene expression.
Because inflammation and infection constitute
the practical problem in cystic fibrosis, antibio-
tics and anti-inflammatory drugs are systemati-
cally administrated to treat CF patients. The
present state of the art about these molecules
suggests that they might affect the epithelial cell
functions. Thus, we investigated the actions
exerted by two different anti-inflammatory drugs
(aspirin and dexamethasone) on CFTR gene
expression.
Two adenocarcinoma cell lines (HT29 and T84
cells) known to express large amounts of CFTR
protein served as experimental models. We
found that IFN,, at low concentrations (from 0.1
up to 100 IU/ml), down-regulated CFTR gene
expression at mRNA and protein levels through a
dose-dependent post-transcriptional mechanism.
The effect was time-dependent: the IFN,-induced
mRNA decrease was significant at 3 hours and
Mediators of Inflammation Vol 5 1996 137Abstracts
maximal after a 12 hour-incubation. INFz and J3
were inactive on CFTR gene expression in T84
and HT29 cells, suggesting that the effect of IFN,
was specific. The IFN,-induced inhibition of
CFTR gene expression evidenced at mRNA and
protein levels was also found at the functional
level: treatment with IFN, reduced the cAMP-
dependent Cl- fluxes. In HT29 cells, TNFcz,
which is concomitantly produced with IFN,
during the inflammatory and immune reactions,
also reduced CFTR gene expression, and acted
synergistically with IFN,.v
These results suggest that the inflammatory
processes may enhance the CF symptomatology
and impair the efficacity of a gene therapy. Thus,
to prevent the negative action of the two cyto-
kines, we are investigating the effects of two
molecules, representative of the distinct families
of anti-inflammatory drugs, i.e., dexamethasone
as an example of steroid-like molecules and
aspirin as a non-steroid molecule, on CFTR gene
expression. Under experimental conditions used,
dexamethasone (ltmol) does not exert any
effect, either at mRNA or at a functional level. On
the contrary, 48 hour-treatment of the T84 cells
either with aspirin or with salicylic acid (0.5 to
I mM) decreased the amount of CFTR transcripts
and the cAMP-dependent Cl fluxes. The aspirin
effect does not require de novo protein synth-
esis, since it subsists after treatment of the cells
with cycloheximide. This effect is not due to a
primer effect on adenylate cyclase since the for-
skolin-induced cAMP production is not modified
by the treatment of the cells with aspirin (or sal-
icylic acid).
These data suggest that production of IFN,
and TNFcz in response to infections might
worsen lung dysfunction in CF patients, and
create a localized CF phenotype in non-CF
patients with chronic bacterial or inflammatory
lung disorders. Furthermore, our results also
point out new action of aspirin commonly used
as an anti-inflammatory drug in CF. High doses
of aspirin, when applied chronically, might also
diminish CFTR-related C1- secretion and worsen
status of the patient.
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Anti-inflammatory therapy for
fibrosis: rational and prospects
cystic
Michael W. Konstan and Melvin Berger
Department of Pediatrics, Case Western Reserve
University School of Medicine, Cleveland, Ohio 44106,
USA
Many lines of evidence suggest that the accumu-
lation of neutrophils into the airways is excessive
and plays a major role in the lung destruction
that continues to be the primary cause of mor-
bidity and mortality in CF. In addition to the
destructive effects, there are many ways in which
neutrophil products cause dysfunction of the
lung and its defence mechanisms. These have
been amply reviewed by other speakers at this
symposium. Several recent studies2’ including
our own work on patients with relatively mild
lung disease,
4 make it clear that this excessive
inflammatory process begins very early during
the course of CF and continues unabatedly,
although its intensity does vary from time to
time.5 Chronic infection in the lung undoubtedly
is a major stimulus for this inflammatory
response, and exacerbations of infection clearly
lead to increased numbers of neutrophils and
their damaging products. Some recent observa-
tions su,gest that inflammation may precede
infection and/or that regulation of inflamma-
tion in the CF lung may be inherently abnormal,
but the role of infectious exacerbations in
increasing the inflammatory damage cannot be
denied.
Clearly, treatment designed to decrease the
inflammatory damage must include efforts to
prevent and/or decrease the amount of infection.
However, once Pseudomonas becomes firmly
established, infection is rarely eradicated despite
continuing evolution of new antibiotics. Broncho-
dilators, airway clearance techniques and DNase
also contribute to the goal of preseeeing lung
function, but despite all these efforts, the inflam-
matory process continues and inexorably
worsens. For these reasons, additional strategies,
such as anti-inflammatory agents that attempt to
compensate for the basic defect (i.e., by the use
of amiloride and/or UTP) and gene therapy are
all being developed.
In contemplating anti-inflammatory therapy, it
is obvious that the main target must be the neu-
trophil itself. The initial step in migration of neu-
trophils into the lung involves activation and
attraction of the cells by soluble mediators. Many
studies have documented that CF lung secretions
contain high concentrations of all of the major
classes of neutrophil chemo-attractants, most
notably, LTB4, C5a and IL-8 (reviewed in 1). It is
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therefore unlikely that antagonists of the produc-
tion or receptor for any single one of these
would have a major effect. Pharmacologic agents
which might interfere with the adhesion mole-
cules employed by the neutrophil to crawl out of
the small blood vessels and into the epithelium
have not yet reached clinical trials. Thus, the
most practical approach is to interfere directly
with neutrophil migration and function.
Because of the likely side effects of corticos-
teroids, which subsequently proved problematic
in a large clinical trial in the US,
6 we investi-
gated the use of non-steroidal anti-inflammatory
drugs (NSAIDs), in particular, ibuprofen. Ibupro-
fen has direct effects in decreasing neutrophil
migration and degranulation and at high but
achievable concentrations, blocks the release of
LTB4 as well as inhibiting cyclo-oxygenase
(reviewed in 7). Using the delivery of neutro-
phils to the alveolar crevices of the gingiva in
the mouth as a model for the intrabronchial
infection in the lung, we showed that ibuprofen
interfered with movement of neutrophils in vivo
in normal volunteers as well as in CF patients.
8
Most importantly, we found that administration
of ibuprofen to animals with the agar bead
model of chronic Pseudomonas infection
reduced the area of inflammation in the lung
without increasing the burden of infectious
organisms] After these preliminary studies, and
once we had defined the pharmacokinetics of
ibuprofen in patients with CF, we initiated a
four-year clinical trial of this drug in patients
with mild lung disease. Compared with placebo,
ibuprofen-treated patients had significantly less
decline in pulmonary function and Brasfield
chest X-ray scores, preserved their percentage
of ideal body weight, and tended to have fewer
hospital admissions.9 The effect was most pro-
nounced in the youngest age group (5-13
years), the annual rate of decline in the percent
predicted FEV1 was 88% slower for ibuprofen-
treated patients compared to placebo. There
were no significant adverse effects. Clinical use
of ibuprofen is now being implemented
throughout the US and other parts of the
world. Establishing the appropriate dose by
pharmacokinetic studies in each patient is
important in individualizing therapy. Other
NSAID trials have also been initiated and preli-
minary results are promising as well (reviewed
in 10). Reports showing that inflammation is
found even in infants with CF and our results
which showed that the most dramatic effects of
ibuprofen occurred in the youngest patients,
suggest that anti-inflammatory therapy should be
initiated very early in life. Until the potential of
gene therapy is realized, anti-inflammatory
agents are likely to be an increasingly important
part of the therapeutic armamentarium in CF.
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Different approaches to gene therapy
for cystic fibrosis
Patricia Lemarcband
INSERM U25, Facult de Mdecine Necker-Enfants
Malades, 75015 Paris, France
Gene therapy for cystic fibrosis (CF) has been
first developed to replace in vivo the CF defec-
tive gene. Rapid progress towards gene transfer
has been made since the identification of the CF
gene, and the initial complementation experi-
ments provided encouragement to investigators
in search of gene transfer vectors to deliver the
CF gene to airways. The ideal vector would effi-
ciently deliver the gene to the appropriate target
cells without causing toxicity or inflammation.
Although none of the available vectors meets
these criteria, studies in a number of animal
models demonstrated gene transfer to the lung,
and human trials have been initiated using
recombinant adenoviruses and liposomes as
vectors for gene transfer to airway epithelium.
However, the underlying pathophysiology of CF
remains unclear, and several issues have come
up for successful CF gene therapy. First, at the
cellular level, there is abundant evidence that
CFTR is important for several cellular functions.
Although the clinically relevant respiratory mani-
festations of CF are in the airways, it is not possi-
ble to evaluate CFTR function reproducibly in the
human bronchial epithelium in vivo, and thus it
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is difficult to demonstrate at the site of the major effective therapy for end-stage pulmonary failure
clinical manifestations of the disease that a gene caused by CF. However, lung transplantation is
therapy strategy in humans actually corrects the associated with complications such as reperfu-
functional deficiencies (including Cl- conduc- sion injury and graft rejection. Pulmonary
tance and hyperabsorption of Na+) associated oedema with acute respiratory failure occurs in
with mutations in the CFTR gene. Second, at the about 20% of patients after lung transplantation
organ level, CFTR has been localized to both the and is associated with increased early mortality.
surface epithelium and submucosal glands in the This acute respiratory failure results from a
lungs. None of the vectors being used in human complex lung injury with both ischaemic and
trials efficiently achieves gene transfer to submu- reperfusion components. Gene therapy targeted
cosal glands. Thus, if CFTR function in submuco- to the graft offers a promising approach to the
sal glands is necessary for normal airway prevention of these complications, by the trans-
clearance, current approaches are not likely to fer of antioxidant genes such as catalase and/or
impact on disease pathogenesis in the cartilagen- superoxide dismutase genes. As adenovirus
ous airways. Finally, the relative sparing of pul- vectors can transfer genes in vivo to the lung
monary disease in CF patients who carry an vasculature, we evaluated the feasibility of gene
allele encoding a partially defective CFTR mole- transfer to the lung graft in a porcine model of
cule suggests that less than complete genetic left lung allotransplantation, using an adenovirus
reconstitution will be necessary for therapeutic vector containing a reporter gene. Adenovirus-
efficiency. However, in vivo adenovirus-mediated mediated gene transfer to the lung graft was fea-
gene transfer to the airway epithelia of nonhu- sible ex vivo, but several parameters limited gene
man primates tends to be of low efficiency and transfer efficiency and need to be improved
patchy, before clinical application is attempted.
In summary, several key issues will need to be
addressed for successful CF gene therapy. Rrn Besides CF gene transfer, ’non-specific’ gene
therapy strategies which may be applied to CF . Alton EWFW, Geddes DM. Gene therapy for cystic fibrosis: a clinical
perspective. Gene Therapy 1995; 2: 88-95.
patients are being developed, including protec- 2. Wilson JM. Gene therapy for cystic fibrosis: challenges and futures
tion against oxidant stress and improvement of directions. JClin Invest1995; 96: 2547-2554.
lung graft survival.1-3 3. Rosenfeldl{}9: 241-252.MA’
Collins FS. Gene therapy for cystic fibrosis. Chest 1996;
Anti-oxidative gene therapyfor CF
A major part of the airway damage in CF is
mediated by oxidants released by inflammatory
cells on the ai.rway epithelial surface, particularly Germ tlerapy ir ’tR: fibroi
neutrophils. Because the number of neutrophils Gabriel Bellon andAndrea Paviran*
in the epithelial lining fluid (ELF) of individuals Hospices Civils de Lyon, Unite "Pneumologie
with CF are 100- to 1000-fold greater than in Pediatrique-Mucoviscidose", Centre Hospitalier Lyon
normal subjects, the potential burden for oxi- Sud, 69310 Pierre Benite and *Transgene SA, 11 rue
dants on the airway epithelium is enormous. The de Molsheim, 67082 Strasbourg, France
oxidant-antioxidant imbalance is placed further
in favour of the oxidants in that respiratory ELF At present it is conceivable to think that gene
levels of glutathione are markedly reduced in CF therapy represents a way to treat or even prevent
compared with that in normal individuals. A strat- the respiratory manifestations of cystic fibrosis.
egy to protect the epithelium is to augment the Consistent with such a concept, there is sufficient
anti-oxidant screen of the epithelial surface, thus evidence that Ad-CFTR, a recombinant replica-
allowing the inflammatory cells on the epithelial tion-deficient adenovirus expressing the human
surface to phagocytize and kill bacteria, yet pro- cystic fibrosis transmembrane conductance regu-
tecting the epithelium from damage by oxidants lator cDNA, can vectorize the expression of a
released by the phagocytes during this process, functional CFTR (cystic fibrosis transmembrane
Preliminary in vitro studies have demonstrated conductance regulator) to the nasal and airway
that adenovirus mediated gene transfer of the epithelia.
human catalase gene could protect human The clinical protocol was designed to assess
epithelial cells against oxidant stress, the safety of single escalating doses of a replica-
tion defective adenovirus expressing the cystic
Improvement of lung graft survival by gene fibrosis transmembrane conductance regulator
therapy gene (Ad-CFTR) when administered to the tra-
Lung transplantation has rapidly evolved into an cheobronchial portion of the airways and
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whether biological efficacy of CFTR delivery lowing the use of recombinant adenoviruses,
could be demonstrated, including the induction of cellular immunity,
Six cystic fibrosis patients received nasal instil- recombination to produce a replication compe-
lation and subsequent aerosol (Optineb(R), Air tent virus, production of neutralizing antibodies
Liquide, Paris, France) administration of Ad-CFTR reducing the efficacy of further application and
the following day. Doses (pfu) applied to the inflammation at the site of therapy, with potential
nose were 105 (patients SG and PB), 10 systemic consequences. Animal studies have
(patients FP and EP) and 4 x 10 (patients DS addressed some of these important safety issues,
and FG), while aerosolized doses were 10 especially in rodents and non-human primates.
(patients SG and PB), 108 (patients FP and EP) These studies are critical for assessing the poten-
and 5.4 x 10a (patients DS and FG), respectively, tial toxicity associated with direct instillation of
No acute toxic effects, no increase in the titer of recombinant adenoviruses, such as the adeno-
anti-adenovirus antibodies and no spreading or virus containing human CFTR (AdCFTR), on
shedding of Ad-CFTR were detected. In one airways and lung parenchyma.
patient Ad-CFTR DNA was found in the urine
and blood two days after aerosolization. Ad- Pulmonary inflammation in animal species
CFTR DNA was detected in nasal and bronchial The cotton rat provides a good model for safety
brush samples, in BAL, in saliva and tonsils 21, 8, evaluations of human adenovirus-derived
14 and 4 days post virus administrat?on, respec- vectors.6 In this animal model, with regard to the
tively. Ad-CFTR mRNA (RT-PCR on bronchial expression of the transfected gene in targeted
cells) and CFTR protein (immunochemistry on cells, all cell types in the respiratory airway
nasal and bronchial cells) were detected up to epithelium expressed the gene, with a good dis-
14 days following Ad-CFTR administration, tribution of the vector throughout the respiratory
These results show that the nebulization of tract as far as the terminal bronchioles but with
Ad-CFTR is a possible approach for treating the relatively little gene expression in alveolar epithe-
respiratory manifestation of cystic fibrosis, lium.5’1 After in vivo intra-pulmonary administra-
tion of adenoviral vectors, animals displayed
ACKNOWLEDGEMENTS. This work was supported normal behaviour, and no morbidity or mortality
by: Hospices Civils de Lyon, ministare de la Sante, was observed within a wide range of dosages.13
AFLM, Ministere de la Recherche, DRASS Rh6ne-Alpes, In contrast it has been shown a mild to moder-
and Association Expector. ate dose-dependent transient pulmonary inflam-
mation characterized by cellular infiltrates which
disapeared in a few weeks.2’’’1 The nature of
the infiltrate changed from neutrophil-dominated onary intlammatiol eOZlSeeutive to during the first few days to one dominated by
gene transfer mononuclear cells such as macrophages and lym-
Claire Danel phocytes by day 10. No parenchymal, bronchial
Service d’Anatomie Pathologique, Hopital Laennec, or bronchiolar epithelial cell damage or viral
Paris, France inclusions such as those observed after the
administration of the wild-type adenovirus were
3613 To accomplish gene therapy successfully, genetic observed." Furthermore, in animals evaluated
information must be transferred and expressed histologically for pulmonary fibrosis 28 days after
in the target cells. Various vectors such as retro- vector administration, no increase in collagen
viruses, adenoviruses, adeno-associated viruses, fibres or architectural disorders were observed in
liposomes and molecular conjugates have been the peribronchiolar, perivascular, alveolar or
developed to enhance this process. Adenovirus- pleural areas.
based vectors have a number of properties that In non-human primates, baboons or rhesus
make them attractive vehicles for human gene monkeys, the major adverse effect associated
therapy.5’7 Their ability to transfer genetic mate- with intrabronchial instillation of recombinant
rial efficiently into lung epithelial cells has led adenoviruses was pulmonary alveolar inflamma-
them to be chosen for the first trials of human tion. The severity and location of the inflamma-
gene therapy for cystic fibrosis (CF).2’3’5’7’8’10’11 tory infiltrate depended upon the concentration
The success of this approach will depend not of the virus to which the lung tissue was
only on the level and duration of transgene exposed, and the inflammation was not restricted
expression but also on its safety. Important ques- solely to the area where the virus was directly
tions remain regarding the clinical toxicity of infused. Occurrence of inflammation outside the
administration of adenoviral vectors to the CF targeted regions is likely due to spillover during
lung. In theory, several problems may occur fol- virus infusions.9 Post-mortem microscopic analy-
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sis of the lung parenchyma demonstrated a dose Clinical trials
dependent increase in inflammatory cells, primar- Clinical trials have been initiated in CF patients,
ily lymphocytes in the area where AdCFTR was based on nasal and/or lung directed AdCFTR in
delivered and which persisted for at least 2 order to evaluate the safety and efficiency of
months in some animals. This inflammatory gene transfer. One of these studies was per-
reaction appeared to develop over 2-3 weeks formed on four CF patients in whom varying
following gene administration. It started with doses of CFTR recombinant adenovirus (up to
mild to moderate perivascular accumulation of 2 X 109 pfu) were administered in the nose and
lymphocytes, and extended to the lung intersti- two days later in the lungs.2’ Protein and mRNA
tium in animals receiving the highest dose (109 expression were documented in bronchial and
and 10m pfu). Clinical tests did not accurately nasal epithelium. Nevertheless, within 12 hours
reflect the presence of lung inflammation, with of administration of the virus, one of the subjects
the exception of alveolar infiltrates on chest developed a clinical syndrome with fever, hypo-
radiographs and an increase in lymphocytes in tension, multilobar infiltrates and a marked
bronchoalveolar lavage (BAL). 1’9 Abnormalities increase in circulating levels of the inflammatory
that were seen on chest radiographs resolved mediator interleukin-6. No evidence of recombi-
completely on follow-up examinations. The nation or of serum neutralizing antibodies was
animals’ physical appearances and behaviour found. This probably represented an inflamma-
appeared normal throughout the studies. In all tory reaction within the lung, centred around the
these species, cotton rats or non human pri- site of the application of the adenovirus. The
mates, examination of non-respiratory organs symptoms resolved over a period of one month
failed to show any abnormalities attributed to the with no apparent long-term effects. No evidence
transfection, of any contaminating agent was found. This
subject received the highest dose of adenovirus
Mechanisms that contribute to the inflammatory (2 x 109 pfu) in this study, thus it is likely that
responses this syndrome was a dose-related phenomenon,
The precise mechanism of the lung inflamma- offsetting the transfection efficiency advantage of
tion observed in animals after instillation of adenoviruses.
recombinant adenovirus is unknown. Similar his- Animal models, although showing inflamma-
topathologic appearances after administration of tory responses, did not predict the intensity and
different types of replication-deficient adenovirus rapidity of the onset of this clinical syndrome,
such as AdRSVBgal (containing the Escherichia underlining the importance of such human
coli lac Z) or Ad CFTR (containing the normal studies. This could be explained by species dif-
human CFTR cDNA) indicate that the inflamma- ferences, or by significant pre-existing lung
tory response is probably related to adenovirus disease observed in CF subjects. Lack of animal
components rather than to the transfected gene. models of CF have limited the evaluation of gene
It is unlikely that cell lysis from viral replication therapy, because extrapolation to human therapy
initiated the injury. No viral inclusions were seen is difficult. In particular, of the animal models
and no recombinant or wild type viruses were available, none mimics the human CF lung with
detected by culture. The more likely cause to significant pre-existing disease.
the pulmonary inflammation is a response to For some authors, human nasal studies could
viral antigens, possibly related to the antigenicity help predict dose related difficulties observed in
of viral coat protein and cytotoxic T-lymphocyte lung parenchyma.
12 In fact, more extensive
responses. Time course and perivascular lym- testing of gene transfer agents in the nasal
phocytic infiltrates are compatible with a epithelium prior to the lung do not seem helpful
response to foreign antigens. The early appear- because it has been shown that the nasal epithe-
ance of neutrophils is consistent with a non-spe- lium does not mimic the responses observed in
cific host response. Observations have shown the lower airways, particularly in CF subjects.
that bronchial epithelial cells release interleukin- Even though the CF transmembrane conductance
8 (IL-8) after exposure to various mediators regulator mutations are expressed similarly in the
such as mmour necrosis factor (TNF), and that nasal and bronchial epithelium in CF, the inflam-
IL-8 acts as a neutrophil chemo-attractant matory consequences appear to be different,
thought to mediate the non-specific chronic pul- with little inflammation and no change in the
monary inflammation in CF. Replication-deficient proportion of epithelial cells in the nasal epithe-
adenoviral vectors have also been shown to lium, compared with marked neutrophil inflam-
increase IL-8 and ICAM-1 mRNA and protein marion on the epithelial surface and significant
expression in A549, a lung epithelial human cell changes, in epithelial populations in the large
line.13 airways.
4
142 Mediators of Inflammation Vol 5 1996Abstracts
Regarding the toxicity associated with adminis-
tration of El-deleted adenovirus into the airways
of animals, investigations performed in a number
of species, including rodents and non-human pri-
mates, showed that there is a dose dependent
inflammatory response at the site of gene trans-
fer that diminishes without permanent sequelae.
Experience with intrapulmonary instillation of
virus in patients is limited, but is usually unre-
markable at the low doses administered to
patients, except in the case of one patient. This
syndrome was not predicted by the animal
experiments, thus showing the importance of
human studies, especially in CF. In this disorder,
the lack of an animal lung model and the intense
pulmonary inflammation observed complicate the
evaluation of potential adenovirus vector-related
toxicity.
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